Pharmaceutical Care of Aggravating Renal Function Injury in an Elderly Patient with Lung Cancer Undergoing Chemotherapy

doi:10.19803/j.1672-8629.2020.08.09

Abstract

Abstract: Objective To analyze drug-caused aggravation of renal function injury during chemotherapy in order to provide reference for the adjustment and monitoring of clinical chemotherapy. Methods The clinical data of an elderly chemotherapy patient with lung cancer was analyzed retrospectively. All the drugs that might have been associated with his aggravating renal damage were analyzed. Results The correlations between his ongoing renal damage and cisplatin, pemetrexed, radiocontrast agents were considered "possible". At the same time, bevacizumab seemed "suspicious". For patients with renal damage, adequate hydration should be combined with cisplatin or a radiocontrast agent. An interval of more than 72 hours is recommended. Cisplatin or pemetrexed should not be used when CrCl is less than 30 mL/min. Conclusion Multiple drugs with renal toxicity may be used at the same time during clinical practice, so it is important to have an intimate knowledge of properties of drugs while working hard to reduce adverse reactions and improve curative effect.

Key words: cisplatin, pemetrexed, contrast agent, bevacizumab, renal damage

CLC Number:

R916.696

ZHANG Xiumin, CAI Jing. Pharmaceutical Care of Aggravating Renal Function Injury in an Elderly Patient with Lung Cancer Undergoing Chemotherapy[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 491-495.

References

[1] Shirali A, Pazhayattil GS .Drug-induced impairment of renal function[J].International Journal of Nephrology and Renovascular Disease, 2014, 12(7):457-468.
[2] 裴小华, 赵卫红. 老年人肾功能评估现状与进展[J]. 中华老年多器官疾病杂志, 2013, 12(1):77-80.
[3] Launayvacher V, Chatelut E, Lichtman SM, et al.Renal insuff-iciency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations[J]. European Journal of Cancer Supplements, 2007, 5(4):1314.
[4] Arany I, Safirstein RL.Cisplatin nephrotoxicity[J]. Seminars in Nephrology, 2003, 23(5): 460-464.
[5] 银正民, 官成浓, 黄纳新,等. 高剂量与分割剂量顺铂的EP方案治疗晚期非小细胞肺癌(附72例分析)[J]. 中华肿瘤杂志,1995,17(3): 226-228.
[6] 李燕, 沈琳, 李洁, 等. 分次小剂量顺铂联合化疗对胃癌患者肾功能的影响[J]. 癌症, 2007, 26(12): 1354-1356.
[7] Kintzel PE, Dorr RT.Anticancer drug renal toxicity and elimi-nation: dosing guidelines for altered renal function[J]. Cancer Treatment Reviews, 1995, 21(1):0-64.
[8] Launay-Vacher V, Rey JB, Isnard-Bagnis C, et al.Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care[J]. Cancer Chemotherapy and Pharmacology,2008, 61(6):903-909.
[9] Lehane D, Winston A, Gray R, et al.The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity[J]. International Journal of Radiation Oncology Biology Physics, 1979, 5(8):1393-1399.
[10] Alsarraf M, Fletcher W, Oishi N, et al.Cisplatin hydration with and without mannitol diuresis in refractory disseminated malig-nant melanoma: a southwest oncology group study[J]. Cancer Treat Rep, 1982, 66(1):31-35.
[11] Santoso J T, Lucci J A, Coleman R L, et al.Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a rand-omized trial[J]. Cancer Chemotherapy and Pharmacology, 2003,52(1):13-18.
[12] Hazarika M, White RM, Johnson JR, et al.FDA drug approval summaries: Pemetrexed (Alimta )[J]. Oncologist, 2004, 9(5):482-488.
[13] Rinaldi D A, Kuhn JG, Burris HA, et al.A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation[J]. Cancer Chemotherapy and Pharmacology, 1999, 44(5):372-380.
[14] Kono M, Sakata Y, Sugawara T, et al.Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function[J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2014, 41(13):2587-2590.
[15] ChenCY, Lin JW, Huang JW, et al. Estimated Creatinine Clear-ance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. Clinical Lung Cancer, 2015, 16(6):e131-e140.
[16] Funaguchi N, Nakajima Y, Kaito D, et al.[Analysis of Pemet-rexed Monotherapy in Advanced Non-Small Cell Lung CancerPatients with Impaired Renal Function[J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2015, 42(6):705-708.
[17] Jordan H, Craig V, Michael S, et al.Safety of dose-reduced pemetrexed in patients with renal insufficiency[J]. Journal of Oncology Pharmacy Practice, 2019, 25(5):1125-1129.
[18] Zhu X, Wu S, Dahut W L, et al.Risks of Proteinuria and Hyper-tension With Bevacizumab, an Antibody Against Vascular Endo-thelial Growth Factor: Systematic Review and Meta-Analysis[J].American Journal of Kidney Diseases, 2007, 49(2):186-193.
[19] Shord SS, Bressler LR, Tiernery LA, et al.Understand-ing and managing the possible adverse effects associated with bevac-izumab[J]. Am J Health Syst Pharm,2009,66(11):999-1013.
[20] Miller KD, Chap LI, Holmes FA, et al.Randomized phase III trial of capecitabine compared with bevacizumab plus capecita- bine in patients with previously treated metastatic breast cancer.J Clin Oncol,2005,23(4):792-799.
[21] Advani A, Kelly D J, Advani S L, et al.Role of VEGF in main-taining renal structure and function under normotensive and hypertensive conditions[J]. Proceedings of the National Academy of Sciences, 2007, 104(36):14448-14453.
[22] Mohammed NM, Mahfouz A, Achkar K, et al.Contrast-induced nephropathy[J]. HeartViews,2013,14(3):106-116.
[23] Solomon R.The role of osmolality in the incidence of contrast-induced nephropathy: A systematic review of angiographic contrast media in high risk patients[J]. Kidney International,2005, 68(5):2256-2263.
[24] Dussol B.A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients[J]. Neph-rology Dialysis Transplantation, 2006, 21(8):2120-2126.
[25] Trivedi H, Foley WD.Contrast-induced nephropathy after asecond contrast exposure[J]. Renal Failure, 2010, 32(7):796-801.[26] Abujudeh HH, Gee MS , Kaewlai R . In Emergency Situations,Should Serum Creatinine Be Checked in All Patients Before Performing Second Contrast CT Examinations Within 24 Hours?[J].Journal of the American College of Radiology, 2009, 6(4):268-273.
[27] Owen R J, Hiremath S, Myers A, et al.Canadian Association of Radiologists Consensus Guidelines for the Prevention of Contrast-Induced Nephropathy: Update 2012[J]. Canadian Association of Radiologists Journal, 2014, 65(2):96-105.